Antion Biosciences takes allogeneic approach to therapies with microRNA technology
October 21, 2022 -- Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs. Read More
CDMO Lonza continues drive to support cell and gene therapy commercial customers
October 20, 2022 -- In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies. Read More
Low phosphate levels linked with CAR T neurological toxicity
October 20, 2022 -- Patients with hypophosphatemia had higher incidences and more severe neurological side effects on chimeric antigen receptor (CAR) T-cell therapy than those with normal blood phosphate levels, according to a study published October 19 in the journal Cancer Immunology Research. Read More
Cell and gene therapy sector is in midst of an ‘industrial revolution’: Miguel Forte
October 18, 2022 -- Science Advisory Board spoke with Dr. Miguel Forte, CEO of Bone Therapeutics and president-elect of the International Society for Cell & Gene Therapy, at last week’s 2022 Cell & Gene Meeting on the Mesa about the state of the cell and gene therapy sector. Read More
Platform enables precise, efficient delivery of genetic medicines in vivo
October 17, 2022 -- Biotech company Homology Medicines is leveraging 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo via gene therapy or nuclease-free gene editing modality. CEO Albert Seymour spoke with Science Advisory Board about their platform. Read More
Manufacturing remains big challenge for cell and gene therapy industry
October 17, 2022 -- Science Advisory Board spoke with Eric Blair, chief commercial officer for Andelyn Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa about the challenges of manufacturing to meet growing demand in the cell and gene therapy industry. Read More
Gene editing advances continue a pace, but progress is still early: panel
October 17, 2022 -- With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa say they are looking forward to other near- and longer-term breakthrough technologies on the horizon. Read More
Roadblocks continue to hamper CGT companies as they look to commercialize their products
October 14, 2022 -- The cell and gene therapy (CGT) sector will continue to face investment and regulator challenges in the near term. That’s the consensus of companies in the space who participated in a workshop at this week’s Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
FDA biologics chief outlines ways to remove barriers to cell and gene therapies
October 13, 2022 -- At this year's Meeting on the Mesa, the U.S. Food and Drug Administration’s top biologics regulator said the use of a “cookbook” for developing cell and gene therapy products and global regulatory convergence could help to facilitate their development and take them to the next level. Read More
New ARM CEO provides vision for cell and gene therapy sector, need to address stakeholder concerns
October 12, 2022 -- Timothy Hunt, the new CEO of the Alliance for Regenerative Medicine (ARM), kicked off the 2022 Cell & Gene Meeting on the Mesa, laying out his vision for the industry and emphasizing the need to engage all major stakeholders. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter